MERCK & CO., INC.

(MRK)
  Report
Delayed Nyse  -  05/20 04:03:28 pm EDT
93.55 USD   +1.59%
05/20Merck's Keytruda Receives Positive EMA Panel Opinion as Adjuvant Therapy in Skin Cancer
MT
05/20Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
BU
05/20Merck Gets CHMP Backing for Expanded Keytruda Use in Melanoma
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 231 557206 957193 588236 570--
Enterprise Value (EV)1 247 453230 686218 594254 300245 472235 427
P/E ratio 23,9x29,4x14,9x15,3x14,1x12,1x
Yield 2,48%3,03%3,44%2,98%3,22%3,46%
Capitalization / Revenue 4,94x4,31x3,97x4,09x4,17x3,98x
EV / Revenue 5,28x4,81x4,49x4,39x4,33x3,96x
EV / EBITDA 12,6x11,2x10,5x10,6x10,0x8,57x
Price to Book 9,00x8,18x5,07x4,97x4,23x3,37x
Nbr of stocks (in thousands) 2 545 9842 530 0342 525 9442 528 805--
Reference price (USD) 91,081,876,693,693,693,6
Announcement Date 02/05/202002/04/202102/03/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 46 84047 99448 70457 86556 67659 408
EBITDA1 19 57220 57020 91023 99724 47827 479
Operating profit (EBIT)1 15 92016 94517 69622 24622 25225 310
Operating Margin 34,0%35,3%36,3%38,4%39,3%42,6%
Pre-Tax Profit (EBT)1 11 4648 79113 87918 24419 52523 307
Net income1 9 8437 06713 04915 23516 54519 182
Net margin 21,0%14,7%26,8%26,3%29,2%32,3%
EPS2 3,812,785,146,116,647,73
Dividend per Share2 2,262,482,642,793,013,24
Announcement Date 02/05/202002/04/202102/03/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 13 15413 52115 90113 66614 20813 854
EBITDA1 6 1115 6707 5684 9605 9375 206
Operating profit (EBIT)1 5 3524 8356 4484 9525 6074 871
Operating Margin 40,7%35,8%40,6%36,2%39,5%35,2%
Pre-Tax Profit (EBT) ------
Net income1 4 5673 7584 3103 5123 6603 385
Net margin 34,7%27,8%27,1%25,7%25,8%24,4%
EPS2 1,801,481,701,391,491,31
Dividend per Share ------
Announcement Date 10/28/202102/03/202204/28/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 15 89623 72925 00617 7308 902-
Net Cash position1 -----1 142
Leverage (Debt / EBITDA) 0,81x1,15x1,20x0,74x0,36x-0,04x
Free Cash Flow1 9 9675 5698 67414 33817 13218 527
ROE (Net Profit / Equities) 50,9%58,9%41,1%44,7%35,9%34,6%
Shareholders' equity1 19 34812 00131 75034 05646 03155 472
ROA (Net Profit / Asset) 11,8%17,1%13,2%16,8%15,5%-
Assets1 83 51741 23198 64190 580106 573-
Book Value Per Share2 10,110,015,118,822,127,7
Cash Flow per Share2 5,214,045,177,047,948,45
Capex1 3 4734 6844 4483 4493 3823 450
Capex / Sales 7,41%9,76%9,13%5,96%5,97%5,81%
Announcement Date 02/05/202002/04/202102/03/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 236 569 710 088
Net sales (USD) 48 704 000 000
Number of employees 67 500
Sales / Employee (USD) 721 541
Free-Float 70,6%
Free-Float capitalization (USD) 167 084 603 657
Avg. Exchange 20 sessions (USD) 1 259 417 357
Average Daily Capital Traded 0,53%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA